Emitents | Olainfarm, AS (213800WCG52W62ENOP27) |
Veids | Finanšu pārskati |
Valoda | EN |
Statuss | Publicēts |
Versija | |
Datums | 2014-05-30 17:15:14 |
Versijas komentārs | Izlabota neiztulkotā rindkopa |
Teksts |
Olaine, May 30, 2014
Olainfarm Sales in Q1 2014
Reach 23.3 Million Euro, Net Profit Grows by
32%
AS “Olainfarm” has
experienced the most profitable first quarter in its history, as
its profits reached 3.7 million euro and sales were up to 23.3
million euro. Profit has increased by 32%, while sales by
30%, compared to the same period one year ago.
Major sales markets of JSC
Olainfarm during Q1 2014 were Russia, Ukraine, Latvia, Belarus and
the Netherlands.
„Despite very tense
Russia – Ukraine relationships and devaluation of Tenge in
Kazakhstan, we have experienced the most profitable first quarter
in our history. Sales of major products are more even, sales
of registered products are expanding and we plan to start exporting
to Mongolia this year. Sales of nti-tuberculosis product to
WHO are also increasing,” says Valerijs Maligins, Chairman of the
Board of AS „Olainfarm”.
During the 1st quarter of 2014 JSC
Olainfarm sales continued to increase in all of the company’s main
markets, except for Kazakhstan, where they decreased by 50%
year-on-year.
The decrease was due to devaluation of Kazakhstan national currency
Tenge at the beginning of the year.
The biggest increases in sales
during Q1 2014 were achieved in Spain (+181%), Lithuania (+171%),
Ukraine (+157%) and Uzbekistan (+67%).
In total during three months of 2014 products of JSC Olainfarm were
sold to 31 countries in five continents.
During this period 12 registration cases have been approved in
several countries. Several products are still in the process of
obtaining MAs, among other countries, in Poland, Mongolia and
Kosovo. Preclinical trials of R-fenotropil are being conducted and
totally new forms of existing products are being
developed.
JSC Olainfarm budget and operating plan for 2014 sets targets for
consolidated sales to reach 93 million euro and net profit to reach
15 million euro. According to the unaudited report, during the 1st
quarter of 2014 25.1% of the annual sales target and 24.5% of the
annual profit target have been met.
JSC Olainfarm is one of the biggest pharmaceutical companies in
Latvia with more than 40 years of experience in production of
medication and chemical and pharmaceutical products. A basic
principle of company's operations is to produce reliable and
effective top quality products for Latvia and the rest of the
world. Products made by the Group are being exported to more than
35 countries of the world, including the Baltics, Russia, other
CIS, Europe, Asia, North America and Australia.
Information prepared
by: Salvis
Lapins JSC
“Olainfarm” Member of the Management
Board Rupnicu iela 5, Olaine, Latvia, LV
2114 Phone: +371 6 7013
717 Fax: +371 6 7013
777
e-mail: slapinsh@olainfarm.lv
|
Pielikumi |